The Therapeutic Evaluation Of Radiofrequency Ablation Combined With Tegafur,Gimeracil And Oteracil Porassium Capsules Metronomic Chemotherapy For Hepatocellular Carcinoma

Objective:To explore the clinical efficiency and safety of radiofrequency ablation combined with Tegafur, Gimeracil and Oteracil Porassium Capsules(S-1 Capsules) for hepatocellular carcinoma. Methods:Sixty HCC patients included in this study were underwent initial radiofrequency ablation and then they were divided into RFA+S-1 group and RFA control group according to the metronomic chemotherapy either with S-1 or not. The local tumor control and disease free survival outcome between the two groups were compared. Results: Follow-up observation showed that the total control rate after 9 months’ treatment was 93.3% in RFA+S-1 group vs. 73.4% in RFA control group(P =0.038). During the 18 months of follow up, the median time for disease free survival was 16.25 months in RFA+S-1 group vs. 12.25 months in RFA control group(P<0.001). One-year progression free survival rate in RFA group was 53.3%, which was significantly lower than the RFA + S-1 group(83.3%)(P =0.012). The major complication rate was 13.3%. No procedurerelated death or severe complications occurred. Conclusions:Metronomic chemotherapy with S-1 following initial radiofrequency ablation delays tumor progression and prolongs overall survival of patients with HCC tumors.